---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000536"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:45:18.603030+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Teva Q1 GAAP loss $0.86/share; revenue down 8%; cuts FY revenue guidance

## Summary
- GAAP diluted loss per share $0.86 vs. income $0.07 in Q1 2021; non-GAAP EPS $0.55 vs. $0.63.
- Revenue $3.66B, down 8% YoY (5% local currency); FY 2022 revenue guidance lowered to $15.4-$16.0B.
- GAAP operating loss $713M driven by $1.1B opioid litigation settlement provisions.
- COPAXONE revenue outlook cut to ~$750M from ~$850M; adjusted EBITDA and EPS guidance reaffirmed.
- First generic Revlimid launched in US; AJOVY and AUSTEDO growing; opioid settlements with Florida and Rhode Island.

## SEC filing metadata
- accession: 0001157523-22-000536
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752322000536/0001157523-22-000536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752322000536/a52704380.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000536
- JSON: https://secwatch.observer/filing/0001157523-22-000536.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000536.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.